Oral human recombinant epidermal growth factor in the treatment of patients with duodenal ulcer

Revista Espanola de Enfermedades Digestivas

Volumn 88, Issue 6, 1996, Pages 409-413

  Haedo, W ^a   Gonzalez T ^b   Mas J A ^c   Franco, S ^d   Gra, B ^a   Soto, G ^e   Alonso, A ^e   Lopez Saura P ^b  

^a INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

^b Center for Biological Research Cuba   (Cuba)

^c HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^d Hospital Luis Diaz Soto   (Cuba)

^e Natl Coord Ctr for Clin Trials   (Cuba)

Author keywords

EGF; epidermal growth factor; peptic ulcer

Indexed keywords

CIMETIDINE; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GASTRODUODENAL ULCER; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DUODENAL ULCER; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 0029943172     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lam SK. Epidemiology and genetics of peptic ulcer. Gastroenterologia Japonica 1993; 28 (Supplements): 145-157.
2. Sarosiek J, Feng T and McCallum RW. The Interrelationship Between Salivary Epidermal Growth Factor and the Functional Integrity of the Esophageal Mucosal Barrier in the Rat. The American Journal of the Medical Sciences 1991; 302: 359-363.
3. Slomiany BL, Liu J, Yao P, Wu-Wang CY, Keogh JP, Wang SL and Slomiany A. Characterisation of the Epidermal Growth Factor Receptor in the Gastric Mucosa. Digestion 1990; 47: 181-190.
4. Olsen PS, Poulsen SS, Therkelsen K and Nex E. Effect of sialoadenectomy and synthetic human urogastrone on healing of chronic gastric ulcers in rats. Cut 1986; 27: 1443-1449.
5. Olsen PS, Poulsen SS, Therkelsen K and Nex E. Oral administration of synthetic human urogastrone promotes healing of chronic duodenal ulcers in rats. Gastroenterology 1986; 90: 911-917.
6. Konturek SJ, Dembinski A, Warzecha Z, Brzozowski T and Gregory H. Role of epidermal growth factor in healing of chronic ulcers in rats. Gastroenterology 1988; 94: 1300-1307.
7. Kuwahara Y, Sunagawa Y, Imoto Y and Okabe S. Effects of Orally Administered Human Epidermal Growth Factor on Natural and Delayed Healing of Acetic Acid-Induced Gastric Ulcers in Rats. Japan J Pharmacol 1990; 52: 164-166.
8. Gotoh Y, Matsuo Y, Asagi S et al. Randomized, double-blind clinical comparison of epidermal growth factor purified from human urine (MG 111) with cetraxate hydrochloride in the treatment of gastric ulcers. Jpn Pharmacol Ther 1992; 20: S3305-S3331.
9. Cantu TG and Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Int Med 1991; 114: 1027-1039.
10. Brooks WS. Short-and Long-Term management of Peptic Ulcer Disease: Current Role of H2-Antagonists. Hepato-Gastroenterology 1992; 39 (Supplement I): 47-52.
11. Konturek SJ, Brzozowski T, Bielanski W, Warzecha Z and Drozdowicz D. Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats. Am J Med 1989; 86 (Supplement): 32-37.
12. Rees WD. Mechanisms of gastroduodenal protection by sucralfate. Am J Med 1991; 91: 58S-63S.
13. Szabo S. The mode of action of sucralfate: the 1 × 1 × 1 mechanism of action. Scand J Gastroenterol 1991; 185 (Supplement): 7-12.
14. Lee SP. The mode of action of colloidal bismuth subcitrate. Scand J Gastroenterol 1991; 185 (Supplement): 1-6.
15. Konturek SJ, Konturek JW, Kwiecien N, Obtulowicz W, Oleksy J, Hebzda Z and Amon I. Gastric protection by nocloprost against aspirin damage in human. Possible role of epidermal growth factor. Scand J Gastroenterol 1991; 26: 231-236.
16. Itoh M, Imai S, Joh T and Takeuchi T. Prospect of the treatment of human gastric ulcers with orally administered epidermal growth factor. Gastroenterologia Japonica 1993; 28 (Supplement 5): 127-131.
17. Cinza AM, Quintana M, Lombardero J, Poutou R, Pérez E, Pérez LC, Mella CM, Besada V, Padrón G, Castellanos L, Estrada R and Morales-Grille J. A batch process for production of human Epidermal Growth Factor in yeast. Product characterization. Biotecnologia Aplicada 1991; 8: 166-173.
18. Hixson LJ, Kelley CL, Jones WN and Tuohy CD. Current Trends in the Pharmacotherapy for Peptic Ulcer Disease. Arch Intern Med 1992; 152: 726-732.
19. Burgess AW. Epidermal growth factor and transforming growth factor alpha. Er Med Bull 1989; 45: 401-424.
20. Itoh M, Imai S, Joh T, Kawai T, Katsumi K, Yokochi K and Takeuchi T. Protection of gastric mucosa against ethanol-induced injury by intragastric bolus administration of epidermal growth factor combined with hydroxypropyl cellulose. J Clin Gastroenterol 1992; 14 (Supplement 1): S127-130.
21. Thompson JS, Saxena SK, Greaton C, Schultz G and Sharp JG. The effect of route of delivery of urogastrone on intestinal regeneration. Surgery 1989; 106: 45-51.
22. Lechat P and Kisch R. Bismuth-induced encephalopathies: Reappraisal of risks. Gastroenterol Clin Biol 1986; 10: 562-569.
23. Mégraud F and Lamouliatte H. Helicobacter pylori and Duodenal Ulcer, Evidence Suggesting Causation. Digestive Diseases and Sciences 1992; 37: 769-772.